These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28143674)

  • 1. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.
    Begier E; Seiden DJ; Patton M; Zito E; Severs J; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A
    Vaccine; 2017 Feb; 35(8):1132-1139. PubMed ID: 28143674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
    Creech CB; Frenck RW; Sheldon EA; Seiden DJ; Kankam MK; Zito ET; Girgenti D; Severs JM; Immermann FW; McNeil LK; Cooper D; Jansen KU; Gruber W; Eiden J; Anderson AS; Baber J
    Vaccine; 2017 Jan; 35(2):385-394. PubMed ID: 27866765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
    Frenck RW; Creech CB; Sheldon EA; Seiden DJ; Kankam MK; Baber J; Zito E; Hubler R; Eiden J; Severs JM; Sebastian S; Nanra J; Jansen KU; Gruber WC; Anderson AS; Girgenti D
    Vaccine; 2017 Jan; 35(2):375-384. PubMed ID: 27916408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.
    Nissen M; Marshall H; Richmond P; Shakib S; Jiang Q; Cooper D; Rill D; Baber J; Eiden J; Gruber W; Jansen KU; Emini EA; Anderson AS; Zito ET; Girgenti D
    Vaccine; 2015 Apr; 33(15):1846-54. PubMed ID: 25707693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel
    Creech CB; Frenck RW; Fiquet A; Feldman R; Kankam MK; Pathirana S; Baber J; Radley D; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A
    Open Forum Infect Dis; 2020 Jan; 7(1):ofz532. PubMed ID: 31993453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and immunogenicity of a novel 4-antigen
    Inoue M; Yonemura T; Baber J; Shoji Y; Aizawa M; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A
    Hum Vaccin Immunother; 2018; 14(11):2682-2691. PubMed ID: 30084709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a Staphylococcus aureus-cholera toxin A
    Misra N; Wines TF; Knopp CL; Hermann R; Bond L; Mitchell B; McGuire MA; Tinker JK
    Vaccine; 2018 Jun; 36(24):3513-3521. PubMed ID: 29739718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.
    Fattom A; Matalon A; Buerkert J; Taylor K; Damaso S; Boutriau D
    Hum Vaccin Immunother; 2015; 11(3):632-41. PubMed ID: 25483694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease.
    Rozemeijer W; Fink P; Rojas E; Jones CH; Pavliakova D; Giardina P; Murphy E; Liberator P; Jiang Q; Girgenti D; Peters RP; Savelkoul PH; Jansen KU; Anderson AS; Kluytmans J
    PLoS One; 2015; 10(2):e0116945. PubMed ID: 25719409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates.
    Park S; Gerber S; Lee JC
    Infect Immun; 2014 Dec; 82(12):5049-55. PubMed ID: 25245803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.
    Marshall H; Nissen M; Richmond P; Shakib S; Jiang Q; Cooper D; Rill D; Baber J; Eiden J; Gruber WC; Jansen KU; Anderson AS; Zito ET; Girgenti D
    J Infect; 2016 Nov; 73(5):437-454. PubMed ID: 27519620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.
    Li X; Wang X; Thompson CD; Park S; Park WB; Lee JC
    mBio; 2016 Feb; 7(1):e02232-15. PubMed ID: 26838725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.
    Lattar SM; Noto Llana M; Denoël P; Germain S; Buzzola FR; Lee JC; Sordelli DO
    Infect Immun; 2014 Jan; 82(1):83-91. PubMed ID: 24126523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.
    Cheng BL; Nielsen TB; Pantapalangkoor P; Zhao F; Lee JC; Montgomery CP; Luna B; Spellberg B; Daum RS
    Hum Vaccin Immunother; 2017 Jul; 13(7):1609-1614. PubMed ID: 28422567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection.
    Hu DL; Narita K; Hyodo M; Hayakawa Y; Nakane A; Karaolis DK
    Vaccine; 2009 Jul; 27(35):4867-73. PubMed ID: 19406185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage.
    Creech CB; Johnson BG; Alsentzer AR; Hohenboken M; Edwards KM; Talbot TR
    Vaccine; 2009 Dec; 28(1):256-60. PubMed ID: 19799842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
    Levy J; Licini L; Haelterman E; Moris P; Lestrate P; Damaso S; Van Belle P; Boutriau D
    Hum Vaccin Immunother; 2015; 11(3):620-31. PubMed ID: 25715157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery.
    Gurtman A; Begier E; Mohamed N; Baber J; Sabharwal C; Haupt RM; Edwards H; Cooper D; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2019; 15(2):358-370. PubMed ID: 30215582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against Staphylococcus aureus experimental endocarditis using recombinant Lactococcus lactis expressing ClfA or FnbpA.
    Veloso TR; Mancini S; Giddey M; Vouillamoz J; Que YA; Moreillon P; Entenza JM
    Vaccine; 2015 Jul; 33(30):3512-7. PubMed ID: 26048778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus.
    Nour El-Din AN; Shkreta L; Talbot BG; Diarra MS; Lacasse P
    Vaccine; 2006 Mar; 24(12):1997-2006. PubMed ID: 16426711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.